Carvykti
As listed in the register: Carvykti
·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ciltacabtagenum autoleucelum
- Made by
- Janssen-Cilag AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Carvykti ist für die Behandlung von erwachsenen Patienten mit rezidiviertem und refraktärem multiplem Myelom indiziert, die zuvor mindestens zwei Therapielinien erhalten haben, inklusive einem immunmodulatorischen Wirkstoff, einem Proteasom-Inhibitor und einem Anti-CD38-Antikörper, und welche refraktär zu Lenalidomid sind.
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Janssen-Cilag AG |
|---|---|
| Active substance | Ciltacabtagenum autoleucelum |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01XL05 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Packs | 1x30 oder 70ml Beutel |
| Zulassungsnummer | 67956 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.